Our pricing services assist manufacturers in determining and optimizing their assets’ price using robust price elicitation techniques customized to the perceived asset value. MKTXS has successfully advised manufacturers on strategies minimizing/limiting price erosion, such as indication launch sequencing in an increasingly complex and value-based pricing landscape. Additionally, given recent trends, such as external price referencing, parallel trade, and increasing generic entry, MKTXS has provided price-optimizing launch sequence roadmaps for use across countries.
Our pricing experts utilize various direct and indirect methodologies to inform client price decision-making. Conjoint analysis, Van Westendorp (price sensitivity meter), Brand-Price Trade-Off (BPTO), Monadic Pricing, and competitor/analogue price-value tradeoff are some commonly used techniques to optimize price potential of an asset. To supplement these quantitative methods, MKTXS regularly collaborates with an advisory team and global stakeholders to ensure pricing insights are consistent with current healthcare policy.
Our Payer assessment services provide our clients with the access intelligence and strategic foresight necessary to maximize an asset’s value across multiple healthcare markets (reimbursed, mixed, self-pay, etc.). MKTXS commonly engages in post-launch studies to maintain (in cases of generic entry) and potentially further enhance (maximize within patent protection) the Payer perceived value of the asset. As a result of its extensive knowledge of core and emerging market healthcare systems, MKTXS is well placed to provide our clients with the recommendations and insights needed to appropriately communicate value to the stakeholders who will determine access and extent of utilization.
MKTXS is well experienced in conducting both primary and secondary research. Our vast network of Payers and Payer influencers has allowed us to address a broad scope of business questions, such as quantifying the willingness to pay for a therapy fulfilling significant unmet needs, identifying access barriers and opportunities, and outlining evidence requirements across multiple therapeutic areas. Our insights have provided clients with guidance regarding country, region, and global specific action steps to appropriately guide commercial development, in-licensing decisions, P&R negotiation planning, launch sequencing, and various Payer communications and objection handling.